Dr Wayne YH Chang from Taipei, Taiwan, talks about the ‘Current standard of care in advanced disease’, focusing on castrate resistant prostate cancer (CRPC). He addresses current treatment strategies in CRPC, and explores the range of evidence supporting chemotherapy (such as doxetaxel which remains first-line treatment based on clinical study results), as well as the evidence supporting novel secondary hormonal therapies (such as abiraterone acetate and enzalutamide) and bone targeted therapy (such as radium-223). He also reviews the evidence supporting newer therapies under investigation.

This video is sponsored by an educational grant from Janssen Asia Pacific, a pharmaceutical company of Johnson & Johnson